{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:35:34Z","timestamp":1758476134832,"version":"3.41.2"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Schizophrenia (SCZ) and bipolar disorder (BD) are severe mental illnesses (SMI) associated with elevated cardiovascular disease (CVD) risk, including obesity. Leptin and adiponectin are secreted by adipose tissue, with pro- and anti-inflammatory properties, respectively. The second generation antipsychotics (AP) olanzapine, clozapine, and quetiapine have been associated with high leptin levels in SMI. However, the link between inflammatory dysregulation of leptin and adiponectin and CVD risk in SMI, and how this risk is influenced by body mass and AP medication, is still not completely understood. We investigated herein if leptin, adiponectin or their ratio (L\/A ratio) could predict increased CVD risk in SCZ, BD, and in subgroups according to use of antipsychotic (AP) treatment, independent of other cardio-metabolic risk factors.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We measured fasting plasma levels of leptin and adiponectin, and calculated the L\/A ratio in <jats:italic>n<\/jats:italic> = 1,092 patients with SCZ and BD, in subgroups according to AP treatment, and in <jats:italic>n<\/jats:italic> = 176 healthy controls (HC). Differences in the levels of adipokines and L\/A between groups were examined in multivariate analysis of covariance, and the correlations between adipokines and body mass index (BMI) with linear regression. CVD risk was defined by total cholesterol\/high-density lipoprotein (TC\/HDL) and triglyceride\/HDL (TG\/HDL) ratios. The adipokines and L\/A ratios ability to discriminate individuals with TG\/HDL and TC\/HDL ratios above threshold levels was explored by ROC analysis, and we investigated the possible influence of other cardio-metabolic risk factors on the association in logistic regression analyses.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> We observed higher leptin levels and L\/A ratios in SMI compared with HC but found no differences in adiponectin. Both adipokines were highly correlated with BMI. The low adiponectin levels showed a fair discrimination in ROC analysis of individuals with CVD risk, with AUC between 0.7 and 0.8 for both TC\/HDL and TG\/HDL, in all groups examined regardless of diagnosis or AP treatment. Adiponectin remained significantly associated with an elevated TC\/HDL and TG\/HDL ratio in SMI, also after further adjustment with other cardio-metabolic risk factors.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Adiponectin is not dysregulated in SMI but is associated with CVD risk regardless of AP treatment regime.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.623192","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T04:44:57Z","timestamp":1622177097000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Adiponectin Is Related to Cardiovascular Risk in Severe Mental Illness Independent of Antipsychotic Treatment"],"prefix":"10.3389","volume":"12","author":[{"given":"Elina J.","family":"Reponen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Tesli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Dieset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils Eiel","family":"Steen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trude S. J.","family":"Vedal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maren C. F.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Synve H.","family":"Lunding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid T.","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linn N.","family":"R\u00f8devand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole A.","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thor","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.31887\/DCNS.2018.20.1\/bpenninx","article-title":"Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications","volume":"20","author":"Penninx","year":"2018","journal-title":"Dial Clin Neurosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/bdi.12505","article-title":"Twenty-year progression of body mass index in a county-wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis","volume":"19","author":"Strassnig","year":"2017","journal-title":"Bipol Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3389\/fimmu.2019.01587","article-title":"Tissue immune cells fuel obesity-associated inflammation in adipose tissue and beyond","volume":"10","author":"Liu","year":"2019","journal-title":"Front Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cmet.2016.04.011","article-title":"Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk","volume":"23","author":"Stern","year":"2016","journal-title":"Cell Metabol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"9913","DOI":"10.12659\/MSM.918390","article-title":"Leptin expression in human epicardial adipose tissue is associated with local coronary atherosclerosis","volume":"25","author":"Zhang","year":"2019","journal-title":"Med Sci Monitor."},{"key":"B7","doi-asserted-by":"publisher","first-page":"648239","DOI":"10.1155\/2015\/648239","article-title":"Differential effects of leptin and adiponectin in endothelial angiogenesis","volume":"2015","author":"Adya","year":"2015","journal-title":"J Diab Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S0140-6736(03)12255-6","article-title":"Adiponectin and protection against type 2 diabetes mellitus","volume":"361","author":"Spranger","year":"2003","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1161\/01.HYP.0000129281.03801.4b","article-title":"Hypoadiponectinemia is an independent risk factor for hypertension","volume":"43","author":"Iwashima","year":"2004","journal-title":"Hypertension."},{"key":"B10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/aje\/kwk001","article-title":"Association of adiponectin with coronary heart disease and mortality: the rancho bernardo study","volume":"165","author":"Laughlin","year":"2007","journal-title":"Am J Epidemiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jacc.2008.09.035","article-title":"Leptin and coronary heart disease: prospective study and systematic review","volume":"53","author":"Sattar","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.numecd.2018.06.020","article-title":"Leptin to adiponectin ratio - a surrogate biomarker for early detection of metabolic disturbances in obesity","volume":"28","author":"Larsen","year":"2018","journal-title":"Nutr Metabo Cardiov Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.psyneuen.2018.03.021","article-title":"Leptin\/Adiponectin ratio as a potential biomarker for metabolic syndrome in patients with schizophrenia","volume":"92","author":"Chen","year":"2018","journal-title":"Psychoneuroendocrinology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.psyneuen.2015.09.026","article-title":"Are leptin levels increased among people with schizophrenia versus controls? A systematic review and comparative meta-analysis","volume":"63","author":"Stubbs","year":"2016","journal-title":"Psychoneuroendocrinology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.psyneuen.2019.01.001","article-title":"Adipokine levels are associated with insulin resistance in antipsychotics users independently of BMI","volume":"103","author":"Vedal","year":"2019","journal-title":"Psychoneuroendocrinology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e2631","DOI":"10.1002\/hup.2631","article-title":"Association between antipsychotic treatment and leptin levels across multiple psychiatric populations: an updated meta-analysis","volume":"32","author":"Ragguett","year":"2017","journal-title":"Human Psychopharmacol."},{"key":"B17","first-page":"S26","article-title":"Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis","volume":"60","author":"Potvin","year":"2015","journal-title":"Can J Psychiatry."},{"key":"B18","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fpsyt.2020.00672","article-title":"Atherogenic lipid ratios related to myeloperoxidase and c-reactive protein levels in psychotic disorders","volume":"11","author":"Reponen","year":"2020","journal-title":"Front Psychiatry."},{"key":"B19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1600-0447.2008.01244.x","article-title":"The level of illicit drug use is related to symptoms and premorbid functioning in severe mental illness","volume":"118","author":"Ringen","year":"2008","journal-title":"Acta Psychiatrica Scandinavica."},{"volume-title":"Aberrant TNF and Notch Signaling Pathways in Schizophrenia and Bipolar Disorder","year":"2018","author":"Hoseth","key":"B20"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diab Care."},{"key":"B22","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/VHRM.S6269","article-title":"Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention","volume":"5","author":"Millan","year":"2009","journal-title":"Vascular Health Risk Manag."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.amjcard.2012.02.016","article-title":"Relation among the plasma triglyceride\/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women","volume":"109","author":"Salazar","year":"2012","journal-title":"Am J Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eurpsy.2016.02.003","article-title":"Leptin in bipolar disorder: a systematic review and meta-analysis","volume":"35","author":"Fernandes","year":"2016","journal-title":"Eur Psychiatry."},{"key":"B25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.mce.2009.08.018","article-title":"Adipose tissue as an endocrine organ","volume":"316","author":"Galic","year":"2010","journal-title":"Mol Cell Endocrinol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.imlet.2007.07.003","article-title":"Adipose tissue macrophages","volume":"112","author":"Zeyda","year":"2007","journal-title":"Immunol Lett."},{"key":"B27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3389\/fimmu.2018.00169","article-title":"Parallels in immunometabolic adipose tissue dysfunction with ageing and obesity","volume":"9","author":"Trim","year":"2018","journal-title":"Front Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1177\/0269881114555250","article-title":"Effects of olanzapine on the elevation of macrophage infiltration and pro-inflammatory cytokine expression in female rats","volume":"28","author":"Zhang","year":"2014","journal-title":"J Psychopharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00213-011-2555-2","article-title":"Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters","volume":"221","author":"Davey","year":"2012","journal-title":"Psychopharmacology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"158534","DOI":"10.1016\/j.bbalip.2019.158534","article-title":"Adipose tissue as a target for second-generation (atypical) antipsychotics: a molecular view","volume":"1865","author":"Ferreira","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids."},{"key":"B31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.psyneuen.2019.02.019","article-title":"Adiponectin levels in patients with bipolar disorder: a systematic review and meta-analysis","volume":"104","author":"Misiak","year":"2019","journal-title":"Psychoneuroendocrinology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.psyneuen.2015.03.012","article-title":"Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis","volume":"56","author":"Bartoli","year":"2015","journal-title":"Psychoneuroendocrinology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1161\/01.ATV.0000219611.50066.bd","article-title":"Adiponectin is an important determinant of apoA-I catabolism","volume":"26","author":"Verg\u00e8s","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1373\/clinchem.2004.045120","article-title":"Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism","volume":"51","author":"Chan","year":"2005","journal-title":"Clin Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cca.2007.01.026","article-title":"Adiponectin as an anti-inflammatory factor","volume":"380","author":"Ouchi","year":"2007","journal-title":"Clin Chim Acta."},{"key":"B36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1475-2840-13-103","article-title":"Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?","volume":"13","author":"Fisman","year":"2014","journal-title":"Cardiov Diabetol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1161\/01.CIR.0000127953.98131.ED","article-title":"Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages","volume":"109","author":"Kumada","year":"2004","journal-title":"Circulation."},{"key":"B38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1515\/hmbci-2013-0053","article-title":"The role of leptin\/adiponectin ratio in metabolic syndrome and diabetes","volume":"18","author":"L\u00f3pez-Jaramillo","year":"2014","journal-title":"Horm Mol Biol Clin Investig."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1016\/j.dsx.2019.06.005","article-title":"An update on metabolic syndrome: metabolic risk markers and adipokines in the development of metabolic syndrome","volume":"13","author":"Kumari","year":"2019","journal-title":"Diabetes Metab Syndr."},{"key":"B40","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/oby.2007.127","article-title":"Atherogenecity of LDL and unfavorable adipokine profile in metabolically obese, normal-weight woman","volume":"16","author":"Hyun","year":"2008","journal-title":"Obesity."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2017.07.022","article-title":"Adipokines and severity and progression of coronary artery calcium: findings from the rancho bernardo study","volume":"265","author":"Larsen","year":"2017","journal-title":"Atherosclerosis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1160\/TH12-04-0263","article-title":"Relationship of adiponectin and leptin to coronary artery disease, classical cardiovascular risk factors and atherothrombotic biomarkers in the IARS cohort","volume":"107","author":"Shanker","year":"2012","journal-title":"Thromb Haemo."},{"key":"B43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.diabres.2018.06.005","article-title":"The relationship between circulating adiponectin, ADIPOQ variants and incident cardiovascular disease in type 2 diabetes: the fremantle diabetes study","volume":"143","author":"Peters","year":"2018","journal-title":"Diabetes Res Clin Pract."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1161\/ATVBAHA.116.308320","article-title":"Plasma levels of fatty acid\u2013binding protein 4, retinol-binding protein 4, high-molecular-weight adiponectin, and cardiovascular mortality among men with type 2 diabetes: a 22-year prospective study","volume":"36","author":"Liu","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"16589","DOI":"10.1038\/s41598-019-52977-x","article-title":"Total adiponectin is associated with incident cardiovascular and renal events in treated hypertensive patients: subanalysis of the ATTEMPT-CVD randomized trial","volume":"9","author":"Kim-Mitsuyama","year":"2019","journal-title":"Sci Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1210\/jc.2008-0640","article-title":"Adiponectin and risk of coronary heart disease in older men and women","volume":"93","author":"Kizer","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1038\/oby.2008.439","article-title":"Preatherosclerosis and adiponectin subfractions in obese adolescents","volume":"16","author":"Mangge","year":"2008","journal-title":"Obesity."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/mp.2016.225","article-title":"Role of the adipose PPAR\u03b3-adiponectin axis in susceptibility to stress and depression\/anxiety-related behaviors","volume":"22","author":"Guo","year":"2017","journal-title":"Mol Psychiatry."},{"key":"B49","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrm2391","article-title":"Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes","volume":"9","author":"Guilherme","year":"2008","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"246","DOI":"10.9740\/mhc.2017.11.246","article-title":"Management of serious cardiac adverse effects of antipsychotic medications","volume":"7","author":"Stoner","year":"2017","journal-title":"Mental Health Clin."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euroneuro.2014.11.008","article-title":"Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms","volume":"25","author":"Gon\u00e7alves","year":"2015","journal-title":"Euro Neuropsychopharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1210\/jc.2016-1207","article-title":"Weight-loss diets, adiponectin, and changes in cardiometabolic risk in the 2-year POUNDS lost trial","volume":"101","author":"Ma","year":"2016","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.623192\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T04:45:01Z","timestamp":1622177101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.623192\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":52,"alternative-id":["10.3389\/fpsyt.2021.623192"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.623192","relation":{},"ISSN":["1664-0640"],"issn-type":[{"type":"electronic","value":"1664-0640"}],"subject":[],"published":{"date-parts":[[2021,5,28]]},"article-number":"623192"}}